Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition

Knockdown of B-Raf impairs spindle formation and the mitotic checkpoint in human somatic cells

(2011) Meghan Borysova et al.   CELL CYCLE

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

(2011) A. G. Gilmartin et al.   CLINICAL CANCER RESEARCH

Serial Transcriptome Analysis and Cross-Species Integration IdentifiesCentromere-Associated Protein Eas a Novel Neuroblastoma Target

(2010) Naomi J. Balamuth et al.   CANCER RESEARCH

NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome

(2010) Michael Hölzel et al.   CELL

Blockade of the Extracellular Signal-Regulated Kinase Pathway Enhances the Therapeutic Efficacy of Microtubule-Destabilizing Agents in Human Tumor Xenograft Models

(2010) K. Watanabe et al.   CLINICAL CANCER RESEARCH

Phase II Randomized Comparison of Topotecan Plus Cyclophosphamide Versus Topotecan Alone in Children With Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Study

(2010) Wendy B. London et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study

(2010) Rochelle Bagatell et al.   JOURNAL OF CLINICAL ONCOLOGY

Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability

(2010) Y. Degenhardt et al.   MOLECULAR CANCER THERAPEUTICS

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recent Advances in Neuroblastoma

(2010) John M. Maris   NEW ENGLAND JOURNAL OF MEDICINE

Antitumor activity of an allosteric inhibitor of centromere-associated protein-E

(2010) K. W. Wood et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of ALK Signaling for Cancer Therapy

(2009) Y. P. Mosse et al.   CLINICAL CANCER RESEARCH

Trk Receptor Expression and Inhibition in Neuroblastomas

(2009) G. M. Brodeur et al.   CLINICAL CANCER RESEARCH

The activity of extracellular signal-regulated kinase is required during G2/M phase before metaphase–anaphase transition in synchronized leukemia cell lines

(2009) Katarina Matkovic et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Phase I Trial of Oral Irinotecan and Temozolomide for Children With Relapsed High-Risk Neuroblastoma: A New Approach to Neuroblastoma Therapy Consortium Study

(2009) Lars M. Wagner et al.   JOURNAL OF CLINICAL ONCOLOGY

Centromere-Associated Protein E: A Motor That Puts the Brakes on the Mitotic Checkpoint

(2008) K. W. Wood et al.   CLINICAL CANCER RESEARCH

Activating mutations in ALK provide a therapeutic target in neuroblastoma

(2008) Rani E. George et al.   NATURE

Oncogenic mutations of ALK kinase in neuroblastoma

(2008) Yuyan Chen et al.   NATURE

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

(2008) Isabelle Janoueix-Lerosey et al.   NATURE